Scinovex
article Open AccessTop 1% cited

D-type cyclin-dependent kinase activity in mammalian cells.

Molecular and Cellular Biology · 1994 · Vol. 14(3) · pp. 2066–2076
H MatsushimeDawn E. QuelleSheila ShurtleffMasatoshi ShibuyaCharles J. SherrJun‐ya Kato

Abstract

D-type cyclin-dependent kinase activities have not so far been detected in mammalian cells. Lysis of rodent fibroblasts, mouse macrophages, or myeloid cells with Tween 20 followed by precipitation with antibodies to cyclins D1, D2, and D3 or to their major catalytic partner, cyclin-dependent kinase 4 (cdk4), yielded kinase activities in immune complexes which readily phosphorylated the retinoblastoma protein (pRb) but not histone H1 or casein. Virtually all cyclin D1-dependent kinase activity in proliferating macrophages and fibroblasts could be attributed to cdk4. When quiescent cells were stimulated by growth factors to enter the cell cycle, cyclin D1-dependent kinase activity was first detected in mid G1, reached a maximum near the G1/S transition, and remained elevated in proliferating cells. The rate of appearance of kinase activity during G1 phase lagged significantly behind cyclin induction and correlated with the more delayed accumulation of cdk4 and formation of cyclin D1-cdk4 complexes. Thus, cyclin D1-associated kinase activity was not detected during the G0-to-G1 transition, which occurs within the first few hours following growth factor stimulation. Rodent fibroblasts engineered to constitutively overexpress either cyclin D1 alone or cyclin D3 together with cdk4 exhibited greatly elevated cyclin D-dependent kinase activity, which remained absent in quiescent cells but rose to supraphysiologic levels as cells progressed through G1. Therefore, despite continued enforced overproduction of cyclins and cdk4, the assembly of cyclin D-cdk4 complexes and the appearance of their kinase activities remained dependent upon serum stimulation, indicating that upstream regulators must govern formation of the active enzymes.

Cancer-related Molecular PathwaysUbiquitin and proteasome pathwaysCancer Research and TreatmentsCyclin DCyclin-dependent kinase complexCyclin A2BiologyCyclin ACyclin ECyclin-dependent kinase 3Cyclin BCyclin D1Cyclin-dependent kinase 4

MeSH terms

Amino Acid SequenceAnimalsAntibodies, MonoclonalCell CycleCell LineFibroblastsMacrophagesMolecular Sequence DataProtein KinasesProto-Oncogene ProteinsRecombinant ProteinsOncogene ProteinsRetinoblastoma ProteinCyclins3T3 Cells

Funding

  • St. Jude Children's Research Hospital
  • American Lebanese Syrian Associated Charities
  • National Institutes of Health
Citations
1,055
FWCI
34.78
field-weighted impact
References
55
Percentile
100%
vs. same field & year
Citations per year
Cited by
New functional activities for the p21 family of CDK inhibitors.
Genes & Development · 1997 · 1,411 citations
D-type cyclins
Trends in Biochemical Sciences · 1995 · 983 citations
Inhibitors of mammalian G1 cyclin-dependent kinases.
Genes & Development · 1995 · 3,256 citations
The history and future of targeting cyclin-dependent kinases in cancer therapy
Nature Reviews Drug Discovery · 2015 · 1,738 citations
References
Related articles
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.